A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors

Inclusion Criteria: 1. Patients with histologically confirmed advanced (metastatic or unresectable) solid tumors harboring a KRAS G12D mutation. Sign the ICF. 2. Those who fail or are unable to tolerate standard treatment, lack standard treatment, or refuse to receive standard treatment; 3. Those who are able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormality that may alter absorption; 4. Subjects who have at least one measurable lesion documented by computed tomography (CT) and/or magnetic resonance imaging (MRI) as confirmed by the investigator per the RECIST v1.1 criteria. 5. ECOG PS score: 0 or 1; 6. Expected survival time ≥ 3 months; 7. Adequate organ function at screening: Exclusion Criteria: 1. Previously treated with inhibitors against KRAS G12D mutation; 2. The period of time prior to the first dose of investigational product should be at least 28 days from previous treatment or at least 5 half-lives 3. Known immediate or delayed hypersensitivity or idiosyncratic reaction to the ingredients of the preparation used in the trial; 4. Presence of other active malignant tumors in addition to primary tumors; 5. Presence of serious lung diseases at screening; 6. Clinically significant gastrointestinal disorders or other conditions that seriously interfere with drug absorption; 7. Severe hereditary or acquired hemorrhagic diathesis or coagulation disorders; 8. Complicated with clinically significant cardiovascular and cerebrovascular disorders; 9. History of allogeneic hematopoietic stem cell transplantation or organ transplantation (except corneal transplantation); 10. Presence of known mental disorders, epilepsy, dementia, or alcohol and drug abuse that may affect the compliance with study requirements; 11. the investigator determines that participation in the study is not in the best interest of the subject.